Oral MS treatment may cut inflammation and protect nerves

Credibility

Interest

Share:2 min read

Key Takeaway

Early trials suggest an oral drug called vidofludimus calcium may reduce brain inflammation and could help slow disability in some people with MS, with few side effects so far.

What They Found

Vidofludimus calcium is a pill that works in two ways: it limits a chemical pathway cells use to make building blocks (DHODH inhibitor) and it activates a protein linked to nerve health (Nurr1); think of it as both slowing damaging immune activity and supporting nerve cells. In a trial of people with relapsing-remitting MS, the drug led to fewer new spots on MRI scans, which are pictures doctors use to see inflammation in the brain. In a separate small trial of people with progressive MS, the drug showed consistent signs that it might slow worsening of disability across different measures, though these results are early. The medicine was generally well tolerated, meaning most people did not have serious side effects during the studies. Researchers are waiting for larger phase 3 studies to confirm if these early benefits hold true for more people over a longer time.

Who Should Care and Why

People with relapsing-remitting MS should watch these results because fewer MRI lesions often mean less active inflammation, which can mean fewer relapses or flare-ups. People with progressive MS and their caregivers might be hopeful because the drug showed hints of slowing disability, and treatments for progressive forms are harder to find. Doctors and MS care teams should follow phase 3 trial results to know whether to offer this drug as a new option in the future. If proven helpful, an oral pill could be easier to take than some treatments that need injections or hospital visits, making day-to-day management simpler. Families can use this information to ask their care team about ongoing trials or future availability, but should not expect this to replace current treatments yet.

Important Considerations

These are early results from phase 2 trials, which are small and mainly meant to see if the drug might work and is safe; larger phase 3 trials are needed to be sure. MRI improvements do not always lead to better long-term function for every person, so real-world benefits for walking, thinking, or fatigue need confirmation. The drug looked generally safe in the early studies, but rare or long-term side effects may appear only in larger or longer studies, so caution and medical advice are important.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials Early Research

Article Topics:

Dihydroorotate dehydrogenase (DHODH) inhibitorNR4A2)multiple sclerosisnuclear receptor-related 1 protein (Nurr1progressive multiple sclerosisrelapsing-remitting multiple sclerosissecondary progressive multiple sclerosisvidofludimus calcium

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Expert opinion on investigational drugs often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News